Table 2.
SVR Among Patients Treated with LDV/SOF and SOF/VEL for Genotype 1 by IDU and OAT Status, British Columbia Hepatitis Testers Cohort
| Covariates | Off‐OAT/RIDU | Off‐OAT/PIDU | Off‐OAT/NIDU | On‐OAT/IDU | On‐OAT/NIDU | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SVR | No SVR | % SVR | SVR | No SVR | SVR | No SVR | % SVR | SVR | No SVR | SVR | No SVR | % SVR | SVR | No SVR | |
| n (%) | 355 (91) | 35 (9) | 570 (95) | 28 (5) | 3,360 (96) | 155 (4) | 567 (93) | 42 (7) | 163 (95) | 8 (5) | |||||
| Birth cohort | |||||||||||||||
| <1945 | 0 | 0 | 0 | 10 (1.8) | 0 (0) | 100 | 189 (5.6) | 18 (11.6) | 91.3 | 2 (0.4) | 0 (0) | 100 | 1 (0.6) | 0 (0) | 100 |
| 1945‐1964 | 216 (60.8) | 20 (57.1) | 91.5 | 400 (70.2) | 19 (67.9) | 95.5 | 2,716 (80.8) | 117 (75.5) | 95.9 | 298 (52.6) | 15 (35.7) | 95.2 | 98 (60.1) | 4 (50) | 96.1 |
| 1965‐1974 | 85 (23.9) | 12 (34.3) | 87.6 | 123 (21.6) | 7 (25) | 94.6 | 301 (9) | 14 (9) | 95.6 | 156 (27.5) | 14 (33.3) | 91.8 | 37 (22.7) | 3 (37.5) | 92.5 |
| ≥1975 | 54 (15.2) | 3 (8.6) | 94.7 | 37 (6.5) | 2 (7.1) | 94.9 | 154 (4.6) | 6 (3.9) | 96.3 | 111 (19.6) | 13 (31) | 89.5 | 27 (16.6) | 1 (12.5) | 96.4 |
| Age | |||||||||||||||
| <50 years | 118 (33.2) | 13 (37.1) | 90.1 | 135 (23.7) | 7 (25) | 95.1 | 352 (10.5) | 14 (9) | 96.2 | 222 (39.2) | 25 (59.5) | 89.9 | 53 (32.5) | 4 (50) | 93 |
| 50‐60 | 162 (45.6) | 17 (48.6) | 90.5 | 277 (48.6) | 16 (57.1) | 94.5 | 1,356 (40.4) | 47 (30.3) | 96.7 | 261 (46) | 12 (28.6) | 95.6 | 82 (50.3) | 3 (37.5) | 96.5 |
| ≥60 | 75 (21.1) | 5 (14.3) | 93.8 | 158 (27.7) | 5 (17.9) | 96.9 | 1,652 (49.2) | 94 (60.6) | 94.6 | 84 (14.8) | 5 (11.9) | 94.4 | 28 (17.2) | 1 (12.5) | 96.6 |
| Sex | |||||||||||||||
| Female | 108 (30.4) | 9 (25.7) | 92.3 | 205 (36) | 8 (28.6) | 96.2 | 1,136 (33.8) | 31 (20) | 97.3 | 203 (35.8) | 16 (38.1) | 92.7 | 44 (27) | 1 (12.5) | 97.8 |
| Male | 247 (69.6) | 26 (74.3) | 90.5 | 365 (64) | 20 (71.4) | 94.8 | 2,224 (66.2) | 124 (80) | 94.7 | 364 (64.2) | 26 (61.9) | 93.3 | 119 (73) | 7 (87.5) | 94.4 |
| Ethnicity | |||||||||||||||
| White | 342 (96.3) | 34 (97.1) | 91 | 552 (96.8) | 27 (96.4) | 95.3 | 3,058 (91) | 144 (92.9) | 95.5 | 556 (98.1) | 40 (95.2) | 93.3 | 150 (92) | 8 (100) | 94.9 |
| Others | 13 (3.7) | 1 (2.9) | 92.9 | 18 (3.2) | 1 (3.6) | 94.7 | 302 (9) | 11 (7.1) | 96.5 | 11 (1.9) | 2 (4.8) | 84.6 | 13 (8) | 0 (0) | 100 |
| Treatment duration | |||||||||||||||
| <8 weeks | 1 (0.3) | 3 (8.6) | 25 | 4 (0.7) | 1 (3.6) | 80 | 7 (0.2) | 5 (3.2) | 58.3 | 5 (0.9) | 1 (2.4) | 83.3 | |||
| 8 weeks | 66 (18.6) | 8 (22.9) | 89.2 | 77 (13.5) | 7 (25) | 91.7 | 663 (19.7) | 32 (20.6) | 95.4 | 85 (15) | 8 (19) | 91.4 | 25 (15.3) | 1 (12.5) | 96.2 |
| 12 weeks | 247 (69.6) | 20 (57.1) | 92.5 | 413 (72.5) | 17 (60.7) | 96 | 2,180 (64.9) | 85 (54.8) | 96.2 | 415 (73.2) | 31 (73.8) | 93 | 120 (73.6) | 7 (87.5) | 94.5 |
| >12‐<24 weeks | 9 (2.5) | 1 (2.9) | 90 | 3 (0.5) | 1 (3.6) | 75 | 49 (1.5) | 5 (3.2) | 90.7 | 7 (1.2) | 2 (4.8) | 77.8 | 1 (0.6) | 0 (0) | 100 |
| 24 weeks | 32 (9) | 3 (8.6) | 91.4 | 73 (12.8) | 2 (7.1) | 97.3 | 461 (13.7) | 28 (18.1) | 94.3 | 55 (9.7) | 0 (0) | 100 | 17 (10.4) | 0 (0) | 100 |
| Previous treatment | |||||||||||||||
| No | 304 (85.6) | 29 (82.9) | 91.3 | 446 (78.2) | 24 (85.7) | 94.9 | 2,650 (78.9) | 112 (72.3) | 95.9 | 485 (85.5) | 39 (92.9) | 92.6 | 142 (87.1) | 8 (100) | 94.7 |
| Yes | 51 (14.4) | 6 (17.1) | 89.5 | 124 (21.8) | 4 (14.3) | 96.9 | 710 (21.1) | 43 (27.7) | 94.3 | 82 (14.5) | 3 (7.1) | 96.5 | 21 (12.9) | 0 (0) | 100 |
| HCV RNA viral load (IU/mL) | |||||||||||||||
| <124,677 (Q1) | 92 (25.9) | 6 (17.1) | 93.9 | 149 (26.1) | 11 (39.3) | 93.1 | 817 (24.3) | 33 (21.3) | 96.1 | 147 (25.9) | 17 (40.5) | 89.6 | 41 (25.2) | 2 (25) | 95.3 |
| 124,677‐670,049 (Q2) | 103 (29) | 11 (31.4) | 90.4 | 119 (20.9) | 7 (25) | 94.4 | 826 (24.6) | 40 (25.8) | 95.4 | 151 (26.6) | 9 (21.4) | 94.4 | 47 (28.8) | 1 (12.5) | 97.9 |
| 670,049‐2,212,170 (Q3) | 74 (20.8) | 7 (20) | 91.4 | 147 (25.8) | 2 (7.1) | 98.7 | 880 (26.2) | 40 (25.8) | 95.7 | 112 (19.8) | 10 (23.8) | 91.8 | 42 (25.8) | 2 (25) | 95.5 |
| ≥2,212,170 (Q4) | 86 (24.2) | 11 (31.4) | 88.7 | 152 (26.7) | 6 (21.4) | 96.2 | 819 (24.4) | 41 (26.5) | 95.2 | 157 (27.7) | 6 (14.3) | 96.3 | 33 (20.2) | 3 (37.5) | 91.7 |
| Missing | 3 (0.5) | 2 (7.1) | 60 | 18 (0.5) | 1 (0.6) | 94.7 | |||||||||
| Diabetes | |||||||||||||||
| No | 317 (89.3) | 30 (85.7) | 91.4 | 516 (90.5) | 25 (89.3) | 95.4 | 3,044 (90.6) | 135 (87.1) | 95.8 | 517 (91.2) | 40 (95.2) | 92.8 | 161 (98.8) | 8 (100) | 95.3 |
| Yes | 38 (10.7) | 5 (14.3) | 88.4 | 54 (9.5) | 3 (10.7) | 94.7 | 316 (9.4) | 20 (12.9) | 94 | 50 (8.8) | 2 (4.8) | 96.2 | 2 (1.2) | 0 (0) | 100 |
| Cirrhosis | |||||||||||||||
| No | 320 (90.1) | 31 (88.6) | 91.2 | 507 (88.9) | 26 (92.9) | 95.1 | 3,010 (89.6) | 127 (81.9) | 96 | 526 (92.8) | 41 (97.6) | 92.8 | 157 (96.3) | 8 (100) | 95.2 |
| Yes | 35 (9.9) | 4 (11.4) | 89.7 | 63 (11.1) | 2 (7.1) | 97 | 350 (10.4) | 28 (18.1) | 92.6 | 41 (7.2) | 1 (2.4) | 97.6 | 6 (3.7) | 0 (0) | 100 |
| Decompensated cirrhosis | |||||||||||||||
| No | 338 (95.2) | 33 (94.3) | 91.1 | 537 (94.2) | 27 (96.4) | 95.2 | 3,182 (94.7) | 142 (91.6) | 95.7 | 539 (95.1) | 41 (97.6) | 92.9 | 161 (98.8) | 8 (100) | 95.3 |
| Yes | 17 (4.8) | 2 (5.7) | 89.5 | 33 (5.8) | 1 (3.6) | 97.1 | 178 (5.3) | 13 (8.4) | 93.2 | 28 (4.9) | 1 (2.4) | 96.6 | 2 (1.2) | 0 (0) | 100 |
| HBV | |||||||||||||||
| No | 307 (86.5) | 31 (88.6) | 90.8 | 499 (87.5) | 27 (96.4) | 94.9 | 3,200 (95.2) | 151 (97.4) | 95.5 | 487 (85.9) | 37 (88.1) | 92.9 | 152 (93.3) | 8 (100) | 95 |
| Yes | 48 (13.5) | 4 (11.4) | 92.3 | 71 (12.5) | 1 (3.6) | 98.6 | 160 (4.8) | 4 (2.6) | 97.6 | 80 (14.1) | 5 (11.9) | 94.1 | 11 (6.7) | 0 (0) | 100 |
| HIV | |||||||||||||||
| No | 272 (76.6) | 27 (77.1) | 91 | 482 (84.6) | 25 (89.3) | 95.1 | 3,186 (94.8) | 150 (96.8) | 95.5 | 416 (73.4) | 30 (71.4) | 93.3 | 142 (87.1) | 7 (87.5) | 95.3 |
| Yes | 83 (23.4) | 8 (22.9) | 91.2 | 88 (15.4) | 3 (10.7) | 96.7 | 174 (5.2) | 5 (3.2) | 97.2 | 151 (26.6) | 12 (28.6) | 92.6 | 21 (12.9) | 1 (12.5) | 95.5 |
| Problematic alcohol use | |||||||||||||||
| Recent | 145 (40.8) | 9 (25.7) | 94.2 | 63 (11.1) | 2 (7.1) | 96.9 | 141 (4.2) | 10 (6.5) | 93.4 | 97 (17.1) | 5 (11.9) | 95.1 | 7 (4.3) | 1 (12.5) | 87.5 |
| Past | 89 (25.1) | 9 (25.7) | 90.8 | 257 (45.1) | 10 (35.7) | 96.3 | 327 (9.7) | 12 (7.7) | 96.5 | 199 (35.1) | 12 (28.6) | 94.3 | 28 (17.2) | 0 (0) | 100 |
| None | 121 (34.1) | 17 (48.6) | 87.7 | 250 (43.9) | 16 (57.1) | 94 | 2,892 (86.1) | 133 (85.8) | 95.6 | 271 (47.8) | 25 (59.5) | 91.6 | 128 (78.5) | 7 (87.5) | 94.8 |
| Major mental illness | |||||||||||||||
| No | 119 (33.5) | 13 (37.1) | 90.2 | 220 (38.6) | 12 (42.9) | 94.8 | 2,747 (81.8) | 125 (80.6) | 95.6 | 233 (41.1) | 15 (35.7) | 94 | 128 (78.5) | 8 (100) | 94.1 |
| Yes | 236 (66.5) | 22 (62.9) | 91.5 | 350 (61.4) | 16 (57.1) | 95.6 | 613 (18.2) | 30 (19.4) | 95.3 | 334 (58.9) | 27 (64.3) | 92.5 | 35 (21.5) | 0 (0) | 100 |
| Elixhauser index* | |||||||||||||||
| 0 | 41 (11.5) | 5 (14.3) | 89.1 | 47 (8.2) | 2 (7.1) | 95.9 | 1,640 (48.8) | 65 (41.9) | 96.2 | 65 (11.5) | 6 (14.3) | 91.5 | 112 (68.7) | 7 (87.5) | 94.1 |
| ≥1 | 314 (88.5) | 30 (85.7) | 91.3 | 523 (91.8) | 26 (92.9) | 95.3 | 1,720 (51.2) | 90 (58.1) | 95 | 502 (88.5) | 36 (85.7) | 93.3 | 51 (31.3) | 1 (12.5) | 98.1 |
| Material deprivation | |||||||||||||||
| Q1 (most privileged) | 64 (18) | 6 (17.1) | 91.4 | 78 (13.7) | 2 (7.1) | 97.5 | 485 (14.4) | 28 (18.1) | 94.5 | 114 (20.1) | 6 (14.3) | 95 | 25 (15.3) | 0 (0) | 100 |
| Q2 | 42 (11.8) | 3 (8.6) | 93.3 | 80 (14) | 4 (14.3) | 95.2 | 641 (19.1) | 26 (16.8) | 96.1 | 72 (12.7) | 5 (11.9) | 93.5 | 18 (11) | 3 (37.5) | 85.7 |
| Q3 | 53 (14.9) | 3 (8.6) | 94.6 | 101 (17.7) | 5 (17.9) | 95.3 | 730 (21.7) | 30 (19.4) | 96.1 | 91 (16) | 6 (14.3) | 93.8 | 31 (19) | 0 (0) | 100 |
| Q4 | 81 (22.8) | 10 (28.6) | 89 | 150 (26.3) | 9 (32.1) | 94.3 | 746 (22.2) | 33 (21.3) | 95.8 | 99 (17.5) | 9 (21.4) | 91.7 | 42 (25.8) | 1 (12.5) | 97.7 |
| Q5 (most deprived) | 114 (32.1) | 13 (37.1) | 89.8 | 156 (27.4) | 8 (28.6) | 95.1 | 725 (21.6) | 35 (22.6) | 95.4 | 177 (31.2) | 15 (35.7) | 92.2 | 44 (27) | 4 (50) | 91.7 |
| Unknown | 1 (0.3) | 0 (0) | 100 | 5 (0.9) | 0 (0) | 100 | 33 (1) | 3 (1.9) | 91.7 | 14 (2.5) | 1 (2.4) | 93.3 | 3 (1.8) | 0 (0) | 100 |
| Social deprivation | |||||||||||||||
| Q1 (most privileged) | 22 (6.2) | 3 (8.6) | 88 | 51 (8.9) | 3 (10.7) | 94.4 | 378 (11.3) | 22 (14.2) | 94.5 | 39 (6.9) | 0 (0) | 100 | 22 (13.5) | 1 (12.5) | 95.7 |
| Q2 | 34 (9.6) | 3 (8.6) | 91.9 | 68 (11.9) | 2 (7.1) | 97.1 | 455 (13.5) | 18 (11.6) | 96.2 | 55 (9.7) | 3 (7.1) | 94.8 | 12 (7.4) | 0 (0) | 100 |
| Q3 | 33 (9.3) | 1 (2.9) | 97.1 | 89 (15.6) | 3 (10.7) | 96.7 | 663 (19.7) | 35 (22.6) | 95 | 61 (10.8) | 10 (23.8) | 85.9 | 22 (13.5) | 1 (12.5) | 95.7 |
| Q4 | 67 (18.9) | 4 (11.4) | 94.4 | 127 (22.3) | 6 (21.4) | 95.5 | 814 (24.2) | 31 (20) | 96.3 | 89 (15.7) | 5 (11.9) | 94.7 | 34 (20.9) | 0 (0) | 100 |
| Q5 (most deprived) | 198 (55.8) | 24 (68.6) | 89.2 | 230 (40.4) | 14 (50) | 94.3 | 1,017 (30.3) | 46 (29.7) | 95.7 | 309 (54.5) | 23 (54.8) | 93.1 | 70 (42.9) | 6 (75) | 92.1 |
| Unknown | 1 (0.3) | 0 (0) | 100 | 5 (0.9) | 0 (0) | 100 | 33 (1) | 3 (1.9) | 91.7 | 14 (2.5) | 1 (2.4) | 93.3 | 3 (1.8) | 0 (0) | 100 |
| Treatment year | |||||||||||||||
| 2010‐2014 | 5 (1.4) | 0 (0) | 100 | 6 (1.1) | 0 (0) | 100 | 73 (2.2) | 3 (1.9) | 96.1 | 4 (0.7) | 0 (0) | 100 | |||
| 2015‐2017 | 350 (98.6) | 35 (100) | 90.9 | 564 (98.9) | 28 (100) | 95.3 | 3,287 (97.8) | 152 (98.1) | 95.6 | 563 (99.3) | 42 (100) | 93.1 | 163 (100) | 8 (100) | 95.3 |
| Treatment type | |||||||||||||||
| LDV/SOF | 210 (59.2) | 17 (48.6) | 92.5 | 364 (63.9) | 11 (39.3) | 97.1 | 2,264 (67.4) | 104 (67.1) | 95.6 | 336 (59.3) | 15 (35.7) | 95.7 | 89 (54.6) | 3 (37.5) | 96.7 |
| LDV/SOF + RBV | 3 (0.8) | 0 (0) | 100 | 6 (1.1) | 0 (0) | 100 | 50 (1.5) | 2 (1.3) | 96.2 | 4 (0.7) | 0 (0) | 100 | 4 (2.5) | 0 (0) | 100 |
| SOF/VEL | 128 (36.1) | 17 (48.6) | 88.3 | 173 (30.4) | 12 (42.9) | 93.5 | 923 (27.5) | 36 (23.2) | 96.2 | 194 (34.2) | 23 (54.8) | 89.4 | 64 (39.3) | 4 (50) | 94.1 |
| SOF/VEL + RBV | 14 (3.9) | 1 (2.9) | 93.3 | 27 (4.7) | 5 (17.9) | 84.4 | 123 (3.7) | 13 (8.4) | 90.4 | 33 (5.8) | 4 (9.5) | 89.2 | 6 (3.7) | 1 (12.5) | 85.7 |
| Genotype | |||||||||||||||
| Genotype 1 | 243 (68.5) | 24 (68.6) | 91 | 430 (75.4) | 17 (60.7) | 96.2 | 2,591 (77.1) | 119 (76.8) | 95.6 | 399 (70.4) | 28 (66.7) | 93.4 | 117 (71.8) | 5 (62.5) | 95.9 |
| Genotype 2 | 19 (5.4) | 1 (2.9) | 95 | 38 (6.7) | 1 (3.6) | 97.4 | 256 (7.6) | 9 (5.8) | 96.6 | 22 (3.9) | 1 (2.4) | 95.7 | 3 (1.8) | 1 (12.5) | 75 |
| Genotype 3 | 82 (23.1) | 9 (25.7) | 90.1 | 83 (14.6) | 9 (32.1) | 90.2 | 348 (10.4) | 23 (14.8) | 93.8 | 123 (21.7) | 12 (28.6) | 91.1 | 39 (23.9) | 2 (25) | 95.1 |
| Other/unknown | 11 (3.1) | 1 (2.9) | 91.7 | 19 (3.3) | 1 (3.6) | 95 | 165 (4.9) | 4 (2.6) | 97.6 | 23 (4.1) | 1 (2.4) | 95.8 | 4 (2.5) | 0 (0) | 100 |
*
Elixhauser comorbidity index measures the number of comorbidities in the administrative data set.